Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

MDXG vs NAUT vs CDNA vs OSUR vs ILMN

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
MDXG
MiMedx Group, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$548M
5Y Perf.-45.7%
NAUT
Nautilus Biotechnology, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$366M
5Y Perf.-73.1%
CDNA
CareDx, Inc

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$1.11B
5Y Perf.-37.2%
OSUR
OraSure Technologies, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$225M
5Y Perf.-73.3%
ILMN
Illumina, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$21.07B
5Y Perf.-60.0%

MDXG vs NAUT vs CDNA vs OSUR vs ILMN — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
MDXG logoMDXG
NAUT logoNAUT
CDNA logoCDNA
OSUR logoOSUR
ILMN logoILMN
IndustryBiotechnologyBiotechnologyMedical - Diagnostics & ResearchMedical - Instruments & SuppliesMedical - Diagnostics & Research
Market Cap$548M$366M$1.11B$225M$21.07B
Revenue (TTM)$389M$0.00$413M$85M$4.39B
Net Income (TTM)$31M$-57M$-8M$-53M$853M
Gross Margin81.0%48.2%38.8%67.1%
Operating Margin10.2%-3.3%-58.6%20.9%
Forward P/E295.2x22.8x26.8x
Total Debt$23M$30M$20M$13M$2.55B
Cash & Equiv.$166M$12M$65M$199K$1.42B

MDXG vs NAUT vs CDNA vs OSUR vs ILMNLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

MDXG
NAUT
CDNA
OSUR
ILMN
StockAug 20May 26Return
MiMedx Group, Inc. (MDXG)10054.3-45.7%
Nautilus Biotechnol… (NAUT)10026.9-73.1%
CareDx, Inc (CDNA)10062.8-37.2%
OraSure Technologie… (OSUR)10026.7-73.3%
Illumina, Inc. (ILMN)10040.0-60.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: MDXG vs NAUT vs CDNA vs OSUR vs ILMN

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDXG and ILMN are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Illumina, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. NAUT and CDNA also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
MDXG
MiMedx Group, Inc.
The Income Pick

MDXG has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.

  • beta 1.22
  • Rev growth 20.0%, EPS growth 14.3%, 3Y rev CAGR 16.1%
  • Lower volatility, beta 1.22, Low D/E 8.8%, current ratio 4.32x
  • Beta 1.22, current ratio 4.32x
Best for: income & stability and growth exposure
NAUT
Nautilus Biotechnology, Inc.
The Momentum Pick

NAUT ranks third and is worth considering specifically for momentum.

  • +311.5% vs MDXG's -47.1%
Best for: momentum
CDNA
CareDx, Inc
The Value Play

CDNA is the clearest fit if your priority is value.

  • Lower P/E (22.8x vs 26.8x)
Best for: value
OSUR
OraSure Technologies, Inc.
The Healthcare Pick

Among these 5 stocks, OSUR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
ILMN
Illumina, Inc.
The Long-Run Compounder

ILMN is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 0.7% 10Y total return vs MDXG's -48.5%
  • 19.4% margin vs OSUR's -61.9%
  • 13.4% ROA vs NAUT's -29.2%, ROIC 16.8% vs -26.0%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthMDXG logoMDXG20.0% revenue growth vs OSUR's -38.1%
ValueCDNA logoCDNALower P/E (22.8x vs 26.8x)
Quality / MarginsILMN logoILMN19.4% margin vs OSUR's -61.9%
Stability / SafetyMDXG logoMDXGBeta 1.22 vs NAUT's 1.82, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)NAUT logoNAUT+311.5% vs MDXG's -47.1%
Efficiency (ROA)ILMN logoILMN13.4% ROA vs NAUT's -29.2%, ROIC 16.8% vs -26.0%

MDXG vs NAUT vs CDNA vs OSUR vs ILMN — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

MDXGMiMedx Group, Inc.
FY 2025
Surgical
100.0%$142M
NAUTNautilus Biotechnology, Inc.

Segment breakdown not available.

CDNACareDx, Inc
FY 2025
Service
85.0%$274M
Product
15.0%$48M
OSUROraSure Technologies, Inc.
FY 2025
Product And Services
94.8%$109M
Other Revenues
5.2%$6M
ILMNIllumina, Inc.
FY 2025
Sequencing
91.8%$4.0B
Microarray
8.2%$358M

MDXG vs NAUT vs CDNA vs OSUR vs ILMN — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMDXGLAGGINGOSUR

Income & Cash Flow (Last 12 Months)

ILMN leads this category, winning 3 of 6 comparable metrics.

ILMN and NAUT operate at a comparable scale, with $4.4B and $0 in trailing revenue. ILMN is the more profitable business, keeping 19.4% of every revenue dollar as net income compared to OSUR's -61.9%. On growth, CDNA holds the edge at +39.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricMDXG logoMDXGMiMedx Group, Inc.NAUT logoNAUTNautilus Biotechn…CDNA logoCDNACareDx, IncOSUR logoOSUROraSure Technolog…ILMN logoILMNIllumina, Inc.
RevenueTrailing 12 months$389M$0$413M$85M$4.4B
EBITDAEarnings before interest/tax$53M-$58M$2M-$45M$1.1B
Net IncomeAfter-tax profit$31M-$57M-$8M-$53M$853M
Free Cash FlowCash after capex$66M-$51M$65M-$33M$989M
Gross MarginGross profit ÷ Revenue+81.0%+48.2%+38.8%+67.1%
Operating MarginEBIT ÷ Revenue+10.2%-3.3%-58.6%+20.9%
Net MarginNet income ÷ Revenue+7.9%-2.0%-61.9%+19.4%
FCF MarginFCF ÷ Revenue+17.0%+15.8%-38.9%+22.5%
Rev. Growth (YoY)Latest quarter vs prior year-33.1%+39.0%-99.9%+4.8%
EPS Growth (YoY)Latest quarter vs prior year-2.4%+7.7%+126.3%-52.4%+6.1%
ILMN leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

MDXG leads this category, winning 3 of 6 comparable metrics.

At 11.5x trailing earnings, MDXG trades at a 55% valuation discount to ILMN's 25.5x P/E. On an enterprise value basis, MDXG's 5.1x EV/EBITDA is more attractive than ILMN's 19.6x.

MetricMDXG logoMDXGMiMedx Group, Inc.NAUT logoNAUTNautilus Biotechn…CDNA logoCDNACareDx, IncOSUR logoOSUROraSure Technolog…ILMN logoILMNIllumina, Inc.
Market CapShares × price$548M$366M$1.1B$225M$21.1B
Enterprise ValueMkt cap + debt − cash$405M$384M$1.1B$238M$22.2B
Trailing P/EPrice ÷ TTM EPS11.53x-6.13x-53.60x-3.33x25.45x
Forward P/EPrice ÷ next-FY EPS est.295.20x22.85x26.77x
PEG RatioP/E ÷ EPS growth rate6.01x
EV / EBITDAEnterprise value multiple5.14x19.58x
Price / SalesMarket cap ÷ Revenue1.31x2.92x1.96x4.86x
Price / BookPrice ÷ Book value/share2.15x2.32x3.77x0.67x7.95x
Price / FCFMarket cap ÷ FCF7.51x30.66x22.63x
MDXG leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

MDXG leads this category, winning 4 of 9 comparable metrics.

ILMN delivers a 32.8% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $-35 for NAUT. OSUR carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ILMN's 0.94x. On the Piotroski fundamental quality scale (0–9), ILMN scores 8/9 vs NAUT's 1/9, reflecting strong financial health.

MetricMDXG logoMDXGMiMedx Group, Inc.NAUT logoNAUTNautilus Biotechn…CDNA logoCDNACareDx, IncOSUR logoOSUROraSure Technolog…ILMN logoILMNIllumina, Inc.
ROE (TTM)Return on equity+12.9%-35.0%-2.6%-15.1%+32.8%
ROA (TTM)Return on assets+9.7%-29.2%-1.9%-12.8%+13.4%
ROICReturn on invested capital+42.3%-26.0%-5.7%-20.0%+16.8%
ROCEReturn on capital employed+25.7%-32.0%-5.8%-16.8%+17.6%
Piotroski ScoreFundamental quality 0–951538
Debt / EquityFinancial leverage0.09x0.19x0.06x0.04x0.94x
Net DebtTotal debt minus cash-$144M$18M-$46M$13M$1.1B
Cash & Equiv.Liquid assets$166M$12M$65M$199,278$1.4B
Total DebtShort + long-term debt$23M$30M$20M$13M$2.6B
Interest CoverageEBIT ÷ Interest expense25.32x12.09x
MDXG leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CDNA leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ILMN five years ago would be worth $3,717 today (with dividends reinvested), compared to $2,759 for CDNA. Over the past 12 months, NAUT leads with a +311.5% total return vs MDXG's -47.1%. The 3-year compound annual growth rate (CAGR) favors CDNA at 37.7% vs OSUR's -23.5% — a key indicator of consistent wealth creation.

MetricMDXG logoMDXGMiMedx Group, Inc.NAUT logoNAUTNautilus Biotechn…CDNA logoCDNACareDx, IncOSUR logoOSUROraSure Technolog…ILMN logoILMNIllumina, Inc.
YTD ReturnYear-to-date-43.1%+50.8%+12.0%+31.5%+3.2%
1-Year ReturnPast 12 months-47.1%+311.5%+45.2%+12.2%+81.7%
3-Year ReturnCumulative with dividends-36.6%+21.0%+161.1%-55.2%-27.1%
5-Year ReturnCumulative with dividends-62.9%-71.3%-72.4%-68.3%-62.8%
10-Year ReturnCumulative with dividends-48.5%-72.4%+385.1%-53.1%+0.7%
CAGR (3Y)Annualised 3-year return-14.1%+6.6%+37.7%-23.5%-10.0%
CDNA leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — MDXG and CDNA each lead in 1 of 2 comparable metrics.

MDXG is the less volatile stock with a 1.22 beta — it tends to amplify market swings less than NAUT's 1.82 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDNA currently trades 92.3% from its 52-week high vs MDXG's 46.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricMDXG logoMDXGMiMedx Group, Inc.NAUT logoNAUTNautilus Biotechn…CDNA logoCDNACareDx, IncOSUR logoOSUROraSure Technolog…ILMN logoILMNIllumina, Inc.
Beta (5Y)Sensitivity to S&P 5001.22x1.82x1.39x1.45x1.23x
52-Week HighHighest price in past year$7.99$4.31$23.24$3.82$155.53
52-Week LowLowest price in past year$3.02$0.62$10.96$2.08$73.86
% of 52W HighCurrent price vs 52-week peak+46.2%+66.8%+92.3%+81.9%+89.2%
RSI (14)Momentum oscillator 0–10049.352.556.447.165.2
Avg Volume (50D)Average daily shares traded1.4M315K667K473K1.5M
Evenly matched — MDXG and CDNA each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: MDXG as "Buy", NAUT as "Buy", CDNA as "Buy", OSUR as "Hold", ILMN as "Buy". Consensus price targets imply 171.0% upside for MDXG (target: $10) vs -13.2% for NAUT (target: $3).

MetricMDXG logoMDXGMiMedx Group, Inc.NAUT logoNAUTNautilus Biotechn…CDNA logoCDNACareDx, IncOSUR logoOSUROraSure Technolog…ILMN logoILMNIllumina, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHoldBuy
Price TargetConsensus 12-month target$10.00$2.50$24.00$4.00$147.38
# AnalystsCovering analysts155131350
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises2
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+0.6%0.0%+7.9%+6.7%+3.5%
Insufficient data to determine a leader in this category.
Key Takeaway

MDXG leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). ILMN leads in 1 (Income & Cash Flow). 1 tied.

Best OverallMiMedx Group, Inc. (MDXG)Leads 2 of 6 categories
Loading custom metrics...

MDXG vs NAUT vs CDNA vs OSUR vs ILMN: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is MDXG or NAUT or CDNA or OSUR or ILMN a better buy right now?

For growth investors, MiMedx Group, Inc.

(MDXG) is the stronger pick with 20. 0% revenue growth year-over-year, versus -38. 1% for OraSure Technologies, Inc. (OSUR). MiMedx Group, Inc. (MDXG) offers the better valuation at 11. 5x trailing P/E (295. 2x forward), making it the more compelling value choice. Analysts rate MiMedx Group, Inc. (MDXG) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — MDXG or NAUT or CDNA or OSUR or ILMN?

On trailing P/E, MiMedx Group, Inc.

(MDXG) is the cheapest at 11. 5x versus Illumina, Inc. at 25. 5x. On forward P/E, CareDx, Inc is actually cheaper at 22. 8x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — MDXG or NAUT or CDNA or OSUR or ILMN?

Over the past 5 years, Illumina, Inc.

(ILMN) delivered a total return of -62. 8%, compared to -72. 4% for CareDx, Inc (CDNA). Over 10 years, the gap is even starker: CDNA returned +385. 1% versus NAUT's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — MDXG or NAUT or CDNA or OSUR or ILMN?

By beta (market sensitivity over 5 years), MiMedx Group, Inc.

(MDXG) is the lower-risk stock at 1. 22β versus Nautilus Biotechnology, Inc. 's 1. 82β — meaning NAUT is approximately 49% more volatile than MDXG relative to the S&P 500. On balance sheet safety, OraSure Technologies, Inc. (OSUR) carries a lower debt/equity ratio of 4% versus 94% for Illumina, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — MDXG or NAUT or CDNA or OSUR or ILMN?

By revenue growth (latest reported year), MiMedx Group, Inc.

(MDXG) is pulling ahead at 20. 0% versus -38. 1% for OraSure Technologies, Inc. (OSUR). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -261. 5% for OraSure Technologies, Inc.. Over a 3-year CAGR, MDXG leads at 16. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — MDXG or NAUT or CDNA or OSUR or ILMN?

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -59. 8% for OraSure Technologies, Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -59. 2% for OSUR. At the gross margin level — before operating expenses — MDXG leads at 82. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is MDXG or NAUT or CDNA or OSUR or ILMN more undervalued right now?

On forward earnings alone, CareDx, Inc (CDNA) trades at 22.

8x forward P/E versus 295. 2x for MiMedx Group, Inc. — 272. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDXG: 171. 0% to $10. 00.

08

Which pays a better dividend — MDXG or NAUT or CDNA or OSUR or ILMN?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is MDXG or NAUT or CDNA or OSUR or ILMN better for a retirement portfolio?

For long-horizon retirement investors, CareDx, Inc (CDNA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+385.

1% 10Y return). Nautilus Biotechnology, Inc. (NAUT) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CDNA: +385. 1%, NAUT: -72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between MDXG and NAUT and CDNA and OSUR and ILMN?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MDXG is a small-cap high-growth stock; NAUT is a small-cap quality compounder stock; CDNA is a small-cap quality compounder stock; OSUR is a small-cap quality compounder stock; ILMN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

MDXG

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

NAUT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

CDNA

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 19%
  • Gross Margin > 28%
Run This Screen
Stocks Like

OSUR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 23%
Run This Screen
Stocks Like

ILMN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 11%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.